Corvus Pharmaceuticals Inc (CRVS)

[kenyonn2000]

I think the frontline setting is a lot tougher. From what I can tell, CHOP and BV-CHP approaches have 80%+ response rates and 40%+ complete remission rates lasting for years, and even some cures, at least in certain subtypes of PTCL. Then there's CAR-T therapies in trials right now--while more risky in terms of side effects, they have very high response rates. All this means I think 818 would have to have eye-popping responses as a mono therapy in a frontline setting.

I wonder if 818 might carve out a market in frontline combo therapy. If it's very well tolerated and it's mechanism of action is in fact doing what Corvus thinks it is, it might make existing treatments even better. CHOP-818?